Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca Canada Inc.
  • Merck Canada Inc.

This publication has 65 references indexed in Scilit: